ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone

Breast Cancer Research

Volumn 14, Issue 6, 2012, Pages

  Mourskaia, Anna A ^a,d   Amir, Eitan ^e   Dong, Zhifeng ^a,d   Tiedemann, Kerstin ^a,b   Cory, Sean ^c,d   Omeroglu, Atilla ^a   Bertos, Nicholas ^a,d   Ouellet, Véronique ^a,d   Clemons, Mark ^f   Scheffer, George L ^g   Park, Morag ^a,d   Hallett, Michael ^c,d   Komarova, Svetlana V ^a,b   Siegel, Peter M ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCC5 PROTEIN; CARRIER PROTEIN; UNCLASSIFIED DRUG; ABCC5 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LASER CAPTURE MICRODISSECTION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIMARY TUMOR; PROTEIN EXPRESSION; TUMOR BIOPSY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE; BONE TUMOR; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; SECONDARY; TUMOR CELL LINE;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OSTEOCLASTS; OSTEOLYSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84869882406     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3361     Document Type: Article

References (78)

1. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425. 10.1038/nrc3055, 21593787.
2. Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011, 7:208-218. 10.1038/nrendo.2010.227, 3134309, 21200394.
3. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005, 10:169-180. 10.1007/s10911-005-5399-8, 16025223.
4. Rose AA, Siegel PM. Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 2006, 93:931-943.
5. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005, 328:679-687. 10.1016/j.bbrc.2004.11.070, 15694401.
6. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009, 310:71-81. 10.1016/j.mce.2009.07.004, 19616059.
7. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res 2010, 12:215. 10.1186/bcr2781, 3046443, 21176175.
8. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006, 24:2261-2267. 10.1200/JCO.2005.03.8802, 16636340.
9. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78. 10.1016/j.ccr.2009.05.017, 2749247, 19573813.
10. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
11. Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel PM. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol 2011, 178:2377-2388. 10.1016/j.ajpath.2011.01.033, 3081179, 21514448.
12. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007, 5:1001-1014. 10.1158/1541-7786.MCR-07-0119, 17951401.
13. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001, 16:1486-1495. 10.1359/jbmr.2001.16.8.1486, 11499871.
14. Arslan C, Sari E, Aksoy S, Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 2011, 15:21-30. 10.1517/14656566.2011.537260, 21105765.
15. St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 2012, 43:398-404. 10.1016/j.humpath.2011.05.009, 21840040.
16. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30:587-592. 10.1200/JCO.2010.33.5232, 22124102.
17. Hilton JF, Amir E, Hopkins S, Nabavi M, DiPrimio G, Sheikh A, Done SJ, Gianfelice D, Kanji F, Dent S, Barth D, Bouganim N, Al-Najjar A, Clemons M. Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat 2011, 129:761-765. 10.1007/s10549-010-1264-6, 21113656.
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
19. The National Center for Biotechnology Information. , http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=njwzhwsagooekps&acc=GSE39494
20. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999, 18:2149-2164. 10.1093/emboj/18.8.2149, 1171299, 10205169.
21. RNAi central. , http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA
22. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005, 37:1289-1295.
23. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55. 539194, 15630443.
24. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C, Olshen AB, Gerald WL, Massague J. Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 2005, 70:149-158. 10.1101/sqb.2005.70.018, 16869748.
25. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52:1399-1405.
26. Armstrong S, Pereverzev A, Dixon SJ, Sims SM. Activation of P2X7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts. J Cell Sci 2009, 122:136-144. 10.1242/jcs.031534, 19066285.
27. Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 2009, 28:1005-1015. 10.1038/onc.2008.454, 19079339.
28. Labelle-Cote M, Dusseault J, Ismail S, Picard-Cloutier A, Siegel PM, Larose L. Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo. BMC Cancer 2011, 11:443. 10.1186/1471-2407-11-443, 3198724, 21992144.
29. Xu AJ, Xia XH, Du ST, Gu JC. Clinical significance of PHPT1 protein expression in lung cancer. Chin Med J (Engl) 2010, 123:3247-3251.
30. McConnell BV, Koto K, Gutierrez-Hartmann A. Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer 2011, 10:75. 10.1186/1476-4598-10-75, 3131252, 21682918.
31. LaLonde DP, Brown MC, Bouverat BP, Turner CE. Actopaxin interacts with TESK1 to regulate cell spreading on fibronectin. J Biol Chem 2005, 280:21680-21688. 10.1074/jbc.M500752200, 15817463.
32. Liu CR, Ma CS, Ning JY, You JF, Liao SL, Zheng J. Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl) 2004, 117:213-218.
33. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007, 98:621-628. 10.1111/j.1349-7006.2007.00434.x, 17355265.
34. Mannello F. What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?. BMC Med 2011, 9:95. 10.1186/1741-7015-9-95, 3169471, 21834986.
35. Steenport M, Khan KM, Du B, Barnhard SE, Dannenberg AJ, Falcone DJ. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 2009, 183:8119-8127. 10.4049/jimmunol.0901925, 19923455.
36. Albig AR, Becenti DJ, Roy TG, Schiemann WP. Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res 2008, 76:7-14. 10.1016/j.mvr.2008.01.001, 2481384, 18417156.
37. Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E, Fried L, Livasy C, Ketelsen D, Nepal DB, Perou CM, Patterson C, Klauber-Demore N. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res 2009, 69:4621-4628. 10.1158/0008-5472.CAN-08-3402, 2699405, 19458075.
38. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011, 20:768-780. 10.1016/j.ccr.2011.10.016, 22172722.
39. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(Suppl 1):3-10.
40. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009, 28:4456-4468. 10.1038/onc.2009.292, 2795793, 19767768.
41. Chan AS, Jensen KK, Skokos D, Doty S, Lederman HK, Kaplan RN, Rafii S, Rivella S, Lyden D. Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PLoS One 2009, 4:e7955. 10.1371/journal.pone.0007955, 2776978, 19956687.
42. Nakayama S, Iida K, Tsuzuki T, Iwashita T, Murakami H, Asai N, Iwata Y, Ichihara M, Ito S, Kawai K, Asai M, Kurokawa K, Takahashi M. Implication of expression of GDNF/Ret signalling components in differentiation of bone marrow haemopoietic cells. Br J Haematol 1999, 105:50-57. 10.1111/j.1365-2141.1999.01311.x, 10233362.
43. Suh HC, Ji M, Gooya J, Lee M, Klarmann KD, Keller JR. Cell-nonautonomous function of Id1 in the hematopoietic progenitor cell niche. Blood 2009, 114:1186-1195. 10.1182/blood-2008-09-179788, 2723014, 19478045.
44. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010, 86:631-637. 10.1016/j.lfs.2010.02.012, 20159023.
45. Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the "pre-metastatic niche": within bone and beyond. Cancer Metastasis Rev 2006, 25:521-529.
46. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011, 121:1298-1312. 10.1172/JCI43414, 3069764, 21436587.
47. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011, 18:1414-1424. 10.1038/cdd.2011.17, 3149740,3149740, 21415859.
48. Kutuzov MA, Bennett N, Andreeva AV. Protein phosphatase with EF-hand domains 2 (PPEF2) is a potent negative regulator of apoptosis signal regulating kinase-1 (ASK1). Int J Biochem Cell Biol 2010, 42:1816-1822. 10.1016/j.biocel.2010.07.014, 20674765.
49. Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 2012, 19:42-50. 10.1038/cdd.2011.121, 21959933.
50. Szigeti A, Bellyei S, Gasz B, Boronkai A, Hocsak E, Minik O, Bognar Z, Varbiro G, Sumegi B, Gallyas F. Induction of necrotic cell death and mitochondrial permeabilization by heme binding protein 2/SOUL. FEBS Lett 2006, 580:6447-6454. 10.1016/j.febslet.2006.10.067, 17098234.
51. Micali N, Ferrai C, Fernandez-Diaz LC, Blasi F, Crippa MP. Prep1 directly regulates the intrinsic apoptotic pathway by controlling Bcl-XL levels. Mol Cell Biol 2009, 29:1143-1151. 10.1128/MCB.01273-08, 2643814, 19103748.
52. Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 2012, 209:275-289. 10.1084/jem.20111117, 3280870, 22271573.
53. Lim S, Choong LY, Kuan CP, Yunhao C, Lim YP. Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression. J Proteome Res 2009, 8:4062-4076. 10.1021/pr900430n, 19530702.
54. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y, Wang S. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008, 261:147-157. 10.1016/j.canlet.2007.11.028, 18171602.
55. Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007, 26:5046-5059. 10.1038/sj.onc.1210318, 17310986.
56. Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 2002, 93:389-396. 10.1111/j.1349-7006.2002.tb01269.x, 11985788.
57. Verjans E, Noetzel E, Bektas N, Schutz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 2009, 9:230. 10.1186/1471-2407-9-230, 2716369, 19602265.
58. Jacquin C, Koczon-Jaremko B, Aguila HL, Leng L, Bucala R, Kuchel GA, Lee SK. Macrophage migration inhibitory factor inhibits osteoclastogenesis. Bone 2009, 45:640-649. 10.1016/j.bone.2009.06.028, 19591967.
59. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012, 83:1084-1103. 10.1016/j.bcp.2012.01.002, 22248732.
60. Human ABC-Transporters. , http://nutrigene.4t.com/humanabc.htm
61. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics 2009, 3:281-290. 2752038,2752038, 19403462.
62. Farke C, Meyer HH, Bruckmaier RM, Albrecht C. Differential expression of ABC transporters and their regulatory genes during lactation and dry period in bovine mammary tissue. J Dairy Res 2008, 75:406-414. 10.1017/S002202990800335X, 18700997.
63. van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, Schinkel AH. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 2007, 27:1247-1253. 10.1128/MCB.01621-06, 1800714, 17145775.
64. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009, 14:3-9. 10.1007/s10911-009-9109-9, 19224345.
65. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000, 275:30069-30074.
66. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005, 4:855-863. 10.1158/1535-7163.MCT-04-0291, 15897250.
67. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K, Fujiwara Y. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006, 99:9-17. 10.1007/s10549-006-9175-2, 16752223.
68. Saravani R, Karami-Tehrani F, Hashemi M, Aghaei M, Edalat R. Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif 2012, 45:199-206. 10.1111/j.1365-2184.2012.00819.x, 22469131.
69. Fallahian F, Karami-Tehrani F, Salami S, Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J 2011, 278:3360-3369. 10.1111/j.1742-4658.2011.08260.x, 21777390.
70. Mujoo K, Sharin VG, Martin E, Choi BK, Sloan C, Nikonoff LE, Kots AY, Murad F. Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation. Nitric Oxide 2010, 22:43-50. 10.1016/j.niox.2009.11.007, 2838505, 19948239.
71. Teixeira CC, Agoston H, Beier F. Nitric oxide, C-type natriuretic peptide and cGMP as regulators of endochondral ossification. Dev Biol 2008, 319:171-178. 10.1016/j.ydbio.2008.04.031, 2526053, 18514181.
72. Babykutty S, Suboj P, Srinivas P, Nair AS, Chandramohan K, Gopala S. Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways. Clin Exp Metast 2012, 29:471-492.
73. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA 2007, 104:16898-16903. 10.1073/pnas.0702761104, 2040425, 17942699.
74. Akool el S, Kleinert H, Hamada FM, Abdelwahab MH, Forstermann U, Pfeilschifter J, Eberhardt W. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003, 23:4901-4916. 10.1128/MCB.23.14.4901-4916.2003, 162218, 12832476.
75. Lubbe WJ, Zuzga DS, Zhou Z, Fu W, Pelta-Heller J, Muschel RJ, Waldman SA, Pitari GM. Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9. Cancer Res 2009, 69:3529-3536. 10.1158/0008-5472.CAN-09-0067, 2688960, 19336567.
76. Dong SS, Williams JP, Jordan SE, Cornwell T, Blair HC. Nitric oxide regulation of cGMP production in osteoclasts. J Cell Biochem 1999, 73:478-487. 10.1002/(SICI)1097-4644(19990615)73:4<478::AID-JCB6>3.0.CO;2-T, 10733342.
77. Yaroslavskiy BB, Li Y, Ferguson DJ, Kalla SE, Oakley JI, Blair HC. Autocrine and paracrine nitric oxide regulate attachment of human osteoclasts. J Cell Biochem 2004, 91:962-972. 10.1002/jcb.20009, 15034931.
78. Yaroslavskiy BB, Zhang Y, Kalla SE, Garcia Palacios V, Sharrow AC, Li Y, Zaidi M, Wu C, Blair HC. NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP. J Cell Sci 2005, 118:5479-5487. 10.1242/jcs.02655, 16291726.